2687-0940Challenges in modern medicine2687-094010.52575/2687-0940-2022-45-3-263-272122CARDIOLOGY<strong>Chronic</strong> <strong>Coronary</strong> <strong>Heart</strong> <strong>Disease</strong><strong>.&nbsp;</strong><strong>Who Needs Enhanced Antithrombotic Therapy?</strong><strong>Chronic</strong> <strong>Coronary</strong> <strong>Heart</strong> <strong>Disease</strong><strong>.&nbsp;</strong><strong>Who Needs Enhanced Antithrombotic Therapy?</strong>PaninaYulia N.PaninaYulia N.doc.panina@yandex.ruVishnevskijValery I.VishnevskijValery I.vishnevsky.orel@mail.ruGromnatskijNikolai I.GromnatskijNikolai I.202245300

The article considers the concept of &laquo;chronic coronary heart disease&raquo;, shows the mechanisms of its development, describes the assessment and treatment of coronary heart disease, which has changed significantly over the past decade. The problem of comorbidity, which is very relevant in the context of the management of patients with coronary heart disease, is investigated. The European recommendations for comorbid patients with coronary heart disease for the treatment and prevention of CV diseases in patients with DM, developed in cooperation with the European Association for the Study of Diabetes Mellitus, are considered. The necessity of adding a second anticoagulant to acetylsalicylic acid for patients with acute coronary syndrome without a high risk of bleeding for long-term secondary prevention is considered. The new recommendations describe the need to prescribe a combination of new oral anticoagulants and acetylsalicylic acid in patients with DM and recurrent peripheral artery disease of the lower extremities, provided there is no high risk of bleeding. The role of antithrombotic therapy in the treatment of patients with chronic coronary heart disease has been shown. It is shown who is prescribed enhanced antithrombotic therapy for coronary heart disease.

The article considers the concept of &laquo;chronic coronary heart disease&raquo;, shows the mechanisms of its development, describes the assessment and treatment of coronary heart disease, which has changed significantly over the past decade. The problem of comorbidity, which is very relevant in the context of the management of patients with coronary heart disease, is investigated. The European recommendations for comorbid patients with coronary heart disease for the treatment and prevention of CV diseases in patients with DM, developed in cooperation with the European Association for the Study of Diabetes Mellitus, are considered. The necessity of adding a second anticoagulant to acetylsalicylic acid for patients with acute coronary syndrome without a high risk of bleeding for long-term secondary prevention is considered. The new recommendations describe the need to prescribe a combination of new oral anticoagulants and acetylsalicylic acid in patients with DM and recurrent peripheral artery disease of the lower extremities, provided there is no high risk of bleeding. The role of antithrombotic therapy in the treatment of patients with chronic coronary heart disease has been shown. It is shown who is prescribed enhanced antithrombotic therapy for coronary heart disease.

сhronic ischemic heart diseasetreatmentantithrombotic therapycomorbid conditionsischemic riskсhronic ischemic heart diseasetreatmentantithrombotic therapycomorbid conditionsischemic riskСписок литературыKlesova E.Yu., Azarova Yu.E., Sunyakina O.A., Polonikov A.V. 2022. Validaciya kratkogo oprosnika dlya ocenki vklada sredovyh faktorov riska v razvitie vozrast-zavisimyh zabolevanij na primere saharnogo diabeta 2 tipa i ishemicheskoj bolezni serdca [Validation of a short questionnaire to assess the contribution of environmental risk factors to the development of age-dependent diseases on the example of type 2 diabetes mellitus and coronary heart disease]. Scientific results of biomedical research. 2022. 8&nbsp;(1): 130&ndash;138. doi: 10.18413/2658-6533-2022-8-1-0-10Kochetkov A.I., Ostroumova O.D., Kravchenko E.V., Bondarecz O.V., Guseva T.F. 2019. Sochetannaya terapiya ingibitorami protonnoj pompy` i klopidogrelom: fokus na serdechno-sosudisty`j risk [Combined therapy with proton pump inhibitors and clopidogrel: focus on cardiovascular risk]. Consilium Medicum. 2019; 21 (1): 56&ndash;66. doi: 10.26442/20751753.2019.1.190194Panina J.N., Vishnevsky V.I. 2021. Antikoagulyantnaya terapiya pri hronicheskoj bolezni pochek i fibrillyacii predserdij u pacientov pozhilogo vozrasta (obzor literatury) [Anticoagulant therapy for chronic kidney disease and atrial fibrillation in elderly patients (literature review)]. Actual problems of medicine. 44&nbsp;(3): 286&ndash;295. doi: 10.52575/2687-0940-2021-44-3-286-295Rojtberg G.E., Slastnikova I.D. 2020. Sovremenny`e podxody` k provedeniyu optimal`noj antitromboticheskoj terapii pri stabil`noj ishemicheskoj bolezni serdcza [Modern approaches to optimal antithrombotic therapy in stable coronary heart disease]. Arxiv`` vnutrennej mediciny`. 2020; 10 (5): 348&ndash;356. doi: 10.20514/2226-6704-2020-10-5-348-356Ameri P., De Marzo V., Zoccai G.B., Tricarico L., Correale M., Brunetti N.D., Canepa M., De&nbsp;Ferrari&nbsp;G.M., Castagno D., Porto I. 2021. Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis. Eur. Heart. J. Cardiovasc. Pharmacother. 2021. Dec 20. doi: 10.1093/ehjcvp/pvab088Anantha-Narayanan M., Garcia S. 2019. Contemporary Approach to Chronic Total Occlusion Interventions. Current treatment options in cardiovascular medicine. PubMed. URL: https://pubmed.ncbi.nlm.nih.gov/30659365/. doi: 10.1007/s11936-019-0704-9Andrade J.G., Deyell M.W., Wong G.C., Macle L. 2018. Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified. Can. J. Cardiol. 2018. Nov; 34 (11): 1426&ndash;1436. doi: 10.1016/j.cjca.2018.08.028Andreini D., Mushtaq S., Pontone G., Conte E., Sonck J., Collet C., Guglielmo M., Baggiano A., Trabattoni D., Galli S., Montorsi P., Ferrari C., Fabbiocchi F., De Martini S., Annoni A., Mancini&nbsp;M.E., Formenti A., Magatelli M., Resta M., Consiglio E., Muscogiuri G., Fiorentini C., Bartorelli A.L., Pepi M. 2018. Rationale and design of advantage (additional diagnostic value of CT perfusion over coronary CT angiography in stented patients with suspected in-stent restenosis or coronary artery disease progression) prospective study. J. Cardiovasc. Comput. Tomogr. 2018 Sep-Oct; 12 (5): 411&ndash;417. doi: 10.1016/j.jcct.2018.06.003Brener S.J., Kirtane A.J., Rinaldi M.J., Stuckey T.D., Witzenbichler B., Weisz G., Neumann F.J., Metzger D.C., Henry T.D., Cox D.A., Duffy P.L., Mazzaferri E.L. Jr., Gurbel P.A., Brodie B.R., Mehran R., McAndrew T., Stone G.W. 2018. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. Circ. Cardiovasc. Interv. 2018 Oct; 11&nbsp;(10). doi: 10.1161/CIRCINTERVENTIONS.118.006853Choi K.H., Song Y.B., Jeong D.S., Jang Y.H., Hong D., Lee S.Y., Youn T., Bak M., Min K.M., Lee J.M., Park T.K., Yang J.H., Hahn J.Y., Choi J.H., Choi S.H., Chung S.R., Cho Y.H., Sung K., Kim W.S., Gwon H.C., Lee Y.T. 2021. Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. stable ischaemic heart disease after coronary artery bypass grafting. Eur. Heart. J. Cardiovasc. Pharmacother. 2021 Nov 3; 7&nbsp;(6): 517&ndash;526. doi: 10.1093/ehjcvp/pvaa080. PMID: 33075126.Dababneh E., Goldstein S. 2022. Chronic Ischemic Heart Disease Selection of Treatment Modality. StatPearls. URL: https://www.statpearls.com/ArticleLibrary/viewarticle/176Dayoub E.J., Nathan A.S., Khatana S.A.M., Seigerman M., Tuteja S., Kobayashi T., Kolansky D., Groeneveld P., Giri J. 2019. Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009&ndash;2016. Circ. Cardiovasc. Interv. 2019; 12 (1). doi: 10.1161/CIRCINTERVENTIONS.118.007434Dellborg M., Bonaca M.P., Storey R.F., Steg P.G., Im K.A., Cohen M., Bhatt D.L., Oude Ophuis T., Budaj A., Hamm C., Spinar J., Kiss R.G., Lopez-Sendon J., Kamensky G., Van de Werf F., Ardissino D., Kontny F., Montalescot G., Johanson P., Bengtsson O., Himmelmann A., Braunwald&nbsp;E., Sabatine M.S. 2019. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur. Heart. J. Cardiovasc. Pharmacother. 2019 Oct 1; 5 (4): 200&ndash;206. doi: 10.1093/ehjcvp/pvz020Frelinger A.L. 3rd, Bhatt D.L., Lee R.D., Mulford D.J., Wu J., Nudurupati S., Nigam A., Lampa M., Brooks J.K., Barnard M.R., Michelson A.D. 2013. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J. Am. Coll. Cardiol. 2013 Feb 26; 61&nbsp;(8). doi: 10.1016/j.jacc.2012.11.040Hiatt W.R., Fowkes F.G., Heizer G., Berger J.S., Baumgartner I., Held P., Katona B.G., Mahaffey K.W., Norgren L., Jones W.S., Blomster J., Milleg&aring;rd M., Reist C., Patel M.R. 2017. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N. Engl. J. Med. 2017 Jan 5; 376 (1): 32&ndash;40. doi: 10.1056/NEJMoa1611688Kamyshnikova L.A., Efremova O.A., Bondarenko E.V., Obolonkova N.I., Bolkhovitina O.A., Yusuf&nbsp;M.W. 2021. Structural and fucntional parameters of the cardiovascular system during atrial fibrillation in patients after stroke. Wiadomosci Lekarskie. Т. 74. № 3 cz 1. С. 465&ndash;470. doi: 10.36740/wlek202103115Kereiakes D.J. 2009. Ischemia is the critical determinant of revascularization benefit: an interventionalist&#39;s perspective of the COURAGE trial.&nbsp;Rev. Cardiovasc. Med.&nbsp;2009; 10 Suppl 2: S45&ndash;52. doi: 10.3909/ricm10S20006Knuuti J.,&nbsp;Wijns W.,&nbsp; Saraste A., Capodanno D., Barbato E., Funck-Brentano C., Prescott E., Storey R., Deaton C., Cuisset T., Agewall S., Dickstein K., Edvardsen T., Escaned J., Gersh B., Svitil P., Gilard M., Hasdai D., Hatala R., Mahfoud F., Masip J., Muneretto C., Valgimigli M., Achenbach&nbsp;S., Bax J., ESC Scientific Document Group.&nbsp;2020. Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology. &nbsp;European Heart Journal, Volume 41, Issue 3, 14 January 2020, Pages 407&ndash;477.Levy B., Buzon J., Kimmoun A. 2019. Inotropes and vasopressors use in cardiogenic shock: when, which and how much? Curr. Opin. Crit. Care. 2019 Aug; 25&nbsp;(4): 384&ndash;390. doi: 10.1097/MCC.0000000000000632Shafeghat M., Aminorroaya A., Rezaei N. 2021. How Stable Ischemic Heart Disease Leads to Acute Coronary Syndrome in COVID-19? Acta Biomed. 2021 Nov 3; 92 (5). doi: 10.23750/abm.v92i5.12013Stankovic G. 2009. Percutaneous coronary intervention for stable patients: is there any benefit beyond symptom relief?&nbsp;Arq. Bras. Cardiol. 2009 Aug; 93 (2): 196&ndash;9. doi: 10.1590/s0066-782x2009000800020Valgimigli M., Bueno H., Byrne R., Jean-Philippe C., Costa F., Jeppsson A., Juni P., Kastrati A., Kolh P., Mauri L., Mantalescot G., Neumann F.J., Levine G., ESC Scientific Document Group. 2018. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart. J. 2018; 39 (3): 213&ndash;60. doi: 10.1093/eurheartj/ehx419Zhao Q., Zhu Y., Xu Z., Cheng Z., Mei J., Chen X., Wang X. 2018. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA. 2018; 319&nbsp;(16). doi: 10.1001/jama.2018.3197